Mereo BioPharma Group plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $49.7M
- Price
- $0.3115
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.48%
- Volume
- 1.2M
About
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Quick stats
Shares outstanding159.6M
Computed float107.5M
Float / shares67.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001719714
AI Summary
AI-generated1/6
majormixedearnings
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Mereo reported a Q2 net loss of $7.0 million, narrowed from $14.6 million in the prior year, with cash and cash equivalents of $30.1 million now expected to fund operations into late 2027.
The company announced an option and license agreement with Sentynl Therapeutics for alvelestat, potentially generating $40 million in upfront payments and up to $435 million in milestones if the option is exercised.
However, Phase 3 studies for setrusumab missed statistical significance on primary fracture reduction endpoints, though they demonstrated significant improvements in bone mineral density and vertebral fractures.
Red flags
- Setrusumab Phase 3 studies (Orbit and Cosmic) did not achieve statistical significance against primary endpoints
- Cash balance of $30.1M remains low, requiring efficient execution or deal monetization